Skip to main content

Nightingale Health Oyj (HEL:HEALTH)

Finland flag Finland · Delayed Price · Currency is EUR
1.195
-0.025 (-2.05%)
At close: Apr 27, 2026
-58.22%
Market Cap 68.21M
Revenue (ttm) 4.80M
Net Income (ttm) -19.07M
Shares Out 60.36M
EPS (ttm) -0.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 129,268
Average Volume 40,029
Open 1.225
Previous Close 1.220
Day's Range 1.145 - 1.225
52-Week Range 1.195 - 2.995
Beta 0.46
RSI 30.80
Earnings Date Jun 3, 2026

About Nightingale Health Oyj

Nightingale Health Oyj, a health technology company, offers advanced health check that detects disease risks in Finland, the United Kingdom, rest of Europe, the United States, and internationally. The company’s Health Check that detects the risks associated with various common chronic diseases from a single blood sample; and Remote Health Check where health check done remotely. It also offers blood analysis, self collection kits, urine analysis, and biomarkers services. It provides its services to research programs, universities, and healthcare... [Read more]

Industry Health Information Services
Sector Healthcare
Founded 2002
Employees 103
Stock Exchange Nasdaq Helsinki
Ticker Symbol HEALTH
Full Company Profile

Financial Performance

In fiscal year 2025, Nightingale Health Oyj's revenue was 4.69 million, an increase of 7.69% compared to the previous year's 4.36 million. Losses were -18.46 million, 5.71% more than in 2024.

Financial Statements

News

Nightingale Health Oyj Earnings Call Transcript: H1 2026

Revenue grew 4% in H1, with strong order book and pilots supporting a reiterated 50% full-year growth target. Major partnerships expanded, new contracts secured, and US market entry advanced with the New York lab permit. H2 focus is on targeted sales and commercial scaling.

7 weeks ago - Transcripts

Nightingale Health Oyj Earnings Call Transcript: H2 2025

Revenue grew 8% year-over-year to €4.7 million, with strong liquidity and no debt. Major milestones included a public sector deal in Finland, U.S. lab expansion, and a new multi-omics research contract. The outlook targets at least 50% revenue growth this year.

7 months ago - Transcripts

Nightingale Health Oyj Earnings Call Transcript: H1 2025

Revenue grew 35% year-over-year to €2.3 million, with improved profitability and a strong €60 million liquidity position. Expansion continued in key markets, new labs were established, and commercial launches are imminent in Singapore and the U.S.

1 year ago - Transcripts

Nightingale Health Oyj Earnings Call Transcript: H2 2024

Revenue grew 4% year-over-year to EUR 4.36 million, with strong progress in international expansion and major healthcare partnerships. The company remains debt-free, maintains a solid cash position, and is focused on scaling adoption and achieving positive EBITDA.

1 year ago - Transcripts

Nightingale Health Oyj Earnings Call Transcript: H1 2024

2 years ago - Transcripts

Nightingale Health Oyj Earnings Call Transcript: H2 2023

2 years ago - Transcripts

Nightingale Health Oyj Earnings Call Transcript: H1 2023

3 years ago - Transcripts

Nightingale Health Oyj Earnings Call Transcript: H1 2022

3 years ago - Transcripts